Krahn M - Search Results

1

Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis.

Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, Raboud JM, Krahn M. Sander B, et al. Among authors: krahn m. PLoS Med. 2010 Apr 6;7(4):e1000256. doi: 10.1371/journal.pmed.1000256. PLoS Med. 2010. PMID: 20386727 Free PMC article.

2

Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.

Krahn M, Detsky AS. Krahn M, et al. Med Decis Making. 1993 Jan-Mar;13(1):4-20. doi: 10.1177/0272989X9301300103. Med Decis Making. 1993. PMID: 8433635

3

Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program.

Krahn M, Guasparini R, Sherman M, Detsky AS. Krahn M, et al. Am J Public Health. 1998 Nov;88(11):1638-44. doi: 10.2105/ajph.88.11.1638. Am J Public Health. 1998. PMID: 9807529 Free PMC article.

4

The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.

Maetzel A, Krahn M, Naglie G. Maetzel A, et al. Among authors: krahn m. Arthritis Rheum. 2003 Jun 15;49(3):283-92. doi: 10.1002/art.11121. Arthritis Rheum. 2003. PMID: 12794781 Free article.

5

Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada.

Krahn MD, John-Baptiste A, Yi Q, Doria A, Remis RS, Ritvo P, Friedman S. Krahn MD, et al. Vaccine. 2005 Feb 18;23(13):1549-58. doi: 10.1016/j.vaccine.2004.09.023. Vaccine. 2005. PMID: 15694507

6

Cohort effects in dynamic models and their impact on vaccination programmes: an example from hepatitis A.

Srinivasa Rao AS, Chen MH, Pham BZ, Tricco AC, Gilca V, Duval B, Krahn MD, Bauch CT. Srinivasa Rao AS, et al. BMC Infect Dis. 2006 Dec 5;6:174. doi: 10.1186/1471-2334-6-174. BMC Infect Dis. 2006. PMID: 17147828 Free PMC article.

7

A dynamic model for assessing universal Hepatitis A vaccination in Canada.

Bauch CT, Rao AS, Pham BZ, Krahn M, Gilca V, Duval B, Chen MH, Tricco AC. Bauch CT, et al. Among authors: krahn m. Vaccine. 2007 Feb 26;25(10):1719-26. doi: 10.1016/j.vaccine.2006.11.020. Epub 2006 Nov 27. Vaccine. 2007. PMID: 17229493

8

Cost-utility of universal hepatitis A vaccination in Canada.

Bauch CT, Anonychuk AM, Pham BZ, Gilca V, Duval B, Krahn MD. Bauch CT, et al. Among authors: krahn md. Vaccine. 2007 Dec 12;25(51):8536-48. doi: 10.1016/j.vaccine.2007.10.001. Epub 2007 Oct 23. Vaccine. 2007. PMID: 17996339

9

Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.

Anonychuk AM, Tricco AC, Bauch CT, Pham B, Gilca V, Duval B, John-Baptiste A, Woo G, Krahn M. Anonychuk AM, et al. Among authors: krahn m. Pharmacoeconomics. 2008;26(1):17-32. doi: 10.2165/00019053-200826010-00003. Pharmacoeconomics. 2008. PMID: 18088156 Review.

10

Modelling mitigation strategies for pandemic (H1N1) 2009.

Gojovic MZ, Sander B, Fisman D, Krahn MD, Bauch CT. Gojovic MZ, et al. CMAJ. 2009 Nov 10;181(10):673-80. doi: 10.1503/cmaj.091641. Epub 2009 Oct 13. CMAJ. 2009. PMID: 19825923 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

576 results

Search Page

Filters